Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Translational Research in Maternal and Pediatric Pharmacology and Therapeutics

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PostedAug 20

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → National Institutes Of Health

Contacts1 person available

OfficeUSA

Organization / Agency

Department Of Health And Human Services → National Institutes Of Health

View Agency Profile

Office AddressUSA

Contacts

contact@example.gov

Full Description

Show more

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), as part of its stewardship of Congressionally-mandated activities under the Best Pharmaceuticals for Children Act (BPCA) and implementation of recommendations of the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC), intends to renew and publish a Notice of Funding Opportunity (NOFO) to solicit applications to promote translational and clinical research in pregnant women, lactating women, infants, children, and adolescents to: (1) advance precision medicine through the development, testing, and implementation of novel tools, models, and other technologies; (2) discover and develop novel therapeutics or enhance the usage of existing drugs for safer and more effective medications; (3) enhance patient-provider communications about drug effectiveness and safety risks; and, (4) optimize the dissemination, implementation, sustainment, and scale-up of evidence-based interventions to these patient populations. The overall goal is to improve safe and effective precision therapeutics during pregnancy, lactation, and across childhood. Applications are not being solicited at this time.

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2

POSTED

DEADLINE

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)

POSTED

DEADLINE

Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)

POSTED

DEADLINE

Established Clinician Investigator Award to Support Mentoring (KS1)The Established Clinician Investigator Award to Support Mentoring (KS1) is a forecast opportunity issued by the National Institutes of Health under the Department of Health and Human Services. This award is designed to provide established clinician investigators with a sustained period of protected time, enabling them to deliver high-quality mentoring and guidance to early-career clinician research scientists. The program is managed by the Division of Biomedical Research Workforce, which serves as the primary point of contact for interested parties. While specific performance locations and set-aside details are not listed, the award aims to strengthen the pipeline of clinician researchers through structured mentorship support.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure – Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC)The National Institutes of Health, through the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute, is seeking to provide continued support for the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). This initiative focuses on conducting clinical trials to improve outcomes for patients experiencing non-stroke neurological and cardiovascular emergencies within pre-hospital or emergency department settings by identifying effective early-stage treatments. The program specifically seeks to establish a Clinical Coordinating Center (CCC) and a Data Coordinating Center (DCC) to support the network's infrastructure. While this notice serves as a forecast to allow potential applicants time to form collaborations and prepare responsive applications, formal solicitations are not currently being accepted.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Mentored Career Transition Award (KT1/R00)The Mentored Career Transition Award (KT1/R00), issued by the National Institutes of Health under the Department of Health and Human Services, is a biphasic grant designed to transition postdoctoral researchers into independent, tenure-track faculty roles. The award provides up to five years of total support, beginning with a mentored career development phase lasting one to two years. The second phase offers up to three years of independent research funding, which is contingent upon the recipient's satisfactory progress during the initial phase and the procurement of an approved, research-intensive faculty position. This forecasted opportunity is managed by the Division of Biomedical Research Workforce.

Professional and Management Development Training

POSTED

DEADLINE

Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure – Clinical Enrollment HubsThe National Institutes of Health, through the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute, is seeking to support the infrastructure for the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). This initiative focuses on establishing clinical enrollment hubs to conduct trials aimed at improving outcomes for individuals experiencing non-stroke neurological and cardiovascular emergencies within pre-hospital or emergency department settings. This notice serves as a forecast to allow potential applicants time to establish collaborations and develop responsive applications. While the program aims to identify effective early-stage treatments, applications are not currently being solicited. Interested parties can contact the NINDS Department of Emergency Medicine for further information.

Ambulance Services

POSTED

DEADLINE

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)The National Institute on Aging is issuing a forecast for the Alzheimer's Drug-Development Program to support the pre-clinical and early-stage clinical Phase I development of novel biologic and small-molecule drug candidates. The program aims to identify treatments that prevent Alzheimer's disease, slow its progression, or address cognitive and behavioral symptoms. Funding is available for academic and biotech researchers to conduct development activities internally or through specialized contract research organizations. The initiative focuses on expanding the portfolio of investigational drug candidates for emerging therapeutic targets and diversifying the therapeutic pipeline to support mono-therapy, combination therapy, and precision medicine approaches. This opportunity will utilize the U01 activity code. While applications are not currently being accepted, this notice serves to allow potential applicants time to establish collaborations and design responsive projects.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Mentored Research Scientist Career Development Award (KR1)The Mentored Research Scientist Career Development Award (KR1), issued by the National Institutes of Health under the Department of Health and Human Services, is designed to support candidates with research doctoral degrees in their pursuit of future research independence. The award provides up to five years of protected time for intensive career development under the guidance of an experienced mentor. This opportunity is currently listed as a forecast with a posted date of August 13, 2026. Interested parties can contact the Division of Biomedical Research Workforce via email at nihtrain@mail.nih.gov for further information.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Mentored Clinician Research Scientist Career Development Award (KC1)The Mentored Clinician Research Scientist Career Development Award (KC1) is a forecast opportunity provided by the National Institutes of Health under the Department of Health and Human Services. This award is designed to support clinician research scientists with clinical doctoral degrees, offering up to five years of protected time to undergo intensive research career development. The primary goal of the program is to prepare these candidates for future research independence through the guidance of an experienced mentor. Interested parties can contact the Division of Biomedical Research Workforce for further information. The award is listed as a forecast with a posted date of August 13, 2026, and detailed information can be accessed through the grants.gov portal.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Partnership with Common Fund Data Ecosystem ResourcesThe NIH Office of Strategic Coordination through its Common Fund is seeking partnerships between Common Fund data programs and external biomedical data resources to improve the reusability and integration of Common Fund datasets within broader scientific ecosystems. The initiative aims to advance the FAIR principles—Findable, Accessible, Interoperable, and Reusable—by fostering collaborations that bridge the Common Fund Data Ecosystem with other significant NIH data platforms such as the HEAL Data Ecosystem, BRAIN Initiative, Cancer Research Data Commons, ImmPort, TOPMed, and the Medical Imaging and Data Resource Center. These partnerships are intended to develop shared resources that enhance data connectivity, enable cross-platform analysis, and promote broader scientific utility of Common Fund data without supporting new clinical trials. The funding opportunity is open to non-CF biomedical data resources that can contribute infrastructure, tools, or expertise to amplify the impact of Common Fund datasets. Applicants must propose concrete plans for integration, interoperability, and sustainability of jointly developed resources. While no specific funding amount or deadline is indicated in the provided data, the solicitation was posted on August 6, 2026, and inquiries may be directed to the Common Fund Data Ecosystem Program via cfde@od.nih.gov. This effort reflects a strategic push by the NIH to unify diverse biomedical data ecosystems under common standards, enabling more comprehensive and efficient data-driven research across disciplines and institutions.

Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services

POSTED

DEADLINE

Transformative Technologies for Experimental and Computational RNome Characterization and Functional AnalysisThe NIH Common Fund, in collaboration with other NIH Institutes and Centers, is preparing to issue a funding opportunity for the Transformative Technologies for Experimental and Computational RNome Characterization and Functional Analysis initiative under the RNomics program. This initiative aims to develop high-risk, early-stage experimental and computational technologies that overcome major limitations in current RNA analysis methods, with a focus on sequencing RNA, detecting modifications, studying RNA function, and analyzing RNA across molecules, cells, and tissues. The program seeks innovations that have not yet been demonstrated at scale or in biologically relevant systems, prioritizing groundbreaking tools that can advance understanding of health and disease through integrated analysis of the entire RNome. This is a two-phase effort, where successful Phase 1 projects will be evaluated for transition to Phase 2, which is designed to deliver validated, widely usable tools for the scientific community. Applications are not currently being accepted; this notice serves as a forecast to allow potential applicants time to form collaborations and refine proposals. The initiative is part of a broader RNomics effort that includes technology enhancement centers, molecular standards, and a coordinating center, all aimed at establishing comprehensive RNA research capabilities. The funding opportunity will be administered by the National Institutes of Health under the Department of Health and Human Services, with a NAICS code of 541715 for research and development in the physical, engineering, and life sciences. All inquiries should be directed to the Common Fund RNomics Program at cfrnomics@od.nih.gov, and further details can be found through the grants.gov listing. The forecast notice was posted on August 5, 2026, with no set-aside designation or specific place of performance indicated.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE